Calls to lower colorectal cancer screening age
Winnipeg Watch
Maralee speaks with Barry Stein of Colorectal Cancer Canada about their push to lower the screening age to 45 years old.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
an hour ago
- CBC
Kingston prison's supervised drug site has had just 1 visitor
More than a year-and-a-half after it opened, a site at a Kingston, Ont., prison where inmates can consume smuggled drugs under medical supervision has only had one user. The overdose prevention service (OPS) at the Collins Bay Institution was set up as a place where prisoners could inject, snort or swallow substances, all with a nurse on standby. It opened on Nov. 28, 2023, becoming the first of its kind in Ontario and only the third in Canada. (Two more OPS sites have opened since). Five people who applied have been approved to use the site so far, but just one has actually done so, and that inmate has only used it a handful of times, beginning in April, CBC has learned. "There's always going to be a bit of a level of distrust, especially with a novel program such as this and a fundamental change to how we are supporting somebody living with addictions," said Matthew Secord, manager of health and rehabilitation at Collins Bay. Secord described the first visit as "a surreal moment," adding it takes "quite a bit of bravery and courage" to try something new — especially inside a prison. As of March 31, 2025, the cost of running the site — which includes salaries plus operational and maintenance costs — has come to $517,000, according to a spokesperson with Correctional Service Canada (CSC). Inmate says visits attract unwanted attention A man who spent more than a year incarcerated at Collins Bay's minimum security section said he's not surprised the site has seen so little use because it means exposing yourself, and potentially your supplier. CBC has agreed not to identify the inmate, who served his time before the consumption site opened, because he believes speaking out could cause problems with his employment. "If you're a drug dealer in prison, you're not going to sell drugs to a guy who's going to go to the guards because ... they're gonna know who you are, and they're gonna pay attention to you," the man explained. That can result in cell searches or being labelled a gang member, he said, describing some correctional officers as "pure haters" who want to punish inmates beyond their sentences. The goal for nearly everyone behind bars is to get out, the former prisoner said, so a prisoner would be foolish to do anything that could risk delaying their chance at parole — especially open drug use. Fewer needles found in cells An "amnesty zone" exists around the consumption site, meaning approved inmates are able to head to the prison's health-care wing and if drugs are found on them, they can't be charged, explained Secord, the head of health services. Once a prisoner arrives, they're provided with clean supplies and given 10 minutes to consume their substance. They're then required to stay for 30 minutes under observation in case of any negative effects. The sites are an initiative supported by both harm reduction advocates and the union representing correctional officers, which sees it as a way to limit the number of needles inside cells and ensure medical staff, not its members, are the ones responding to overdoses. CSC said visits to a consumption site, like all other medical information, are confidential and will only be shared in limited circumstances such as a life-threatening situation. "Participants ... will not be disciplined for using the service, which includes questions about potential impacts on an offender's conditional release, but they may face disciplinary measures if caught with illicit drugs outside of it," wrote spokesperson Mike Shrider in an email. Operating hours an issue Even with that assurance, the worry persists among prisoners, according to Lynne Leonard, who recently retired as a professor with the University of Ottawa's School of Epidemiology and Public Health. Between 2019 and March 2025, she visited four of the five OPS sites across the country — including Collins Bay — spending hours at each speaking confidentially with everyone from the warden to inmates, before writing up recommendations as part of an independent evaluation. Leonard said one of the most stubborn obstacles she encountered was the fear among inmates that visiting an OPS would be reported to the parole board. While that was a requirement in the past, it isn't any longer, the evaluator said, adding she called on CSC to make that distinction clear to inmates in both her 2020 and 2025 reports. Another common complaint is the operating hours for the sites. While they're open during the day, Leonard said prisoners don't want to be under the influence of narcotics during programming, work or meetings with parole officers. Instead, they'd prefer to take drugs during their free time after supper. The evaluator said she's been told by CSC staff that the hours come down to finances and staffing, explaining it can be hard enough to find nurses to work in a prison, let alone someone willing to work until 10 p.m. A move to crystal meth There's also been a change in the inmates' drug of choice. While fentanyl was popular when OPS sites were first opening up, that's no longer the case. "It's now shifted to crystal meth ... resulting in the fact that you can get fentanyl for a candy bar now because nobody wants it, because it's associated with overdoses," Leonard said. Meth is typically smoked, a drug-consumption method that isn't allowed at OPS locations. The drug can also come with "frightening psychotic episodes," she explained. Still, the most obvious and enduring barrier is the pressure that comes from walking through a prison to visit one of the sites. Leonard said beyond concerns about parole or a crackdown by correctional officers, inmates who use an OPS face a more immediate risk — being "muscled" by others eager for their drugs and willing to use violence to get them. "It's not confidential by any means, and that's part of the issue," she said of visiting the site. "Confidentiality is a huge, huge issue." Trying to attract inmates Twenty-three overdoses or suspected overdoses were reported at Collins Bay between 2022 and 2023, according to CSC. Since the OPS opened, that number had dropped to zero, Secord said, explaining the trend toward crystal meth has likely been a major factor. Like Leonard, he identified operating hours, the attention a visit to the site draws, and the change in the drug of choice as barriers to its use. If there's a recommendation to allow smoking substances including meth at the OPS, that option could be discussed in the future, he added. Meanwhile, Secord said staff at Collins Bay will continue to work with its inmate committee and health liaisons to highlight what the site has to offer. Leonard said everyone wants the OPS model to work, but some problems will be easier to solve than others. During her evaluations, she's heard suggestions that the sites should move out of the health services section of prisons, or that they should be placed on a range of cells specifically for inmates who are using substances. The former inmate said the focus should be on rehab, not drug use, and argued CSC will always have a hard time convincing prisoners that using an OPS won't hurt their hopes of release. "I think inmates have to be assured that it's genuine for their own health, their own life," he explained. "You have to entice them and to make them feel that this is not gonna harm me."
CTV News
3 hours ago
- CTV News
Canadian Food Inspection Agency finds rare disease at B.C. commercial pigeon premises
The Canadian Food Inspection Agency in Ottawa on Wednesday, June 26, 2019. The agency says it has uncovered a case of Newcastle disease at a commercial pigeon operation in Chilliwack, B.C. THE CANADIAN PRESS/Sean Kilpatrick Canada's food inspection agency says it has uncovered a case of Newcastle disease at a commercial pigeon operation in Chilliwack, B.C., requiring the birds to be culled and the premises to be disinfected. The Canadian Food Inspection Agency says the virus affects both wild and domestic birds and can cause pink eye in humans. It says the ailment is of great concern to the world's agricultural community since it's highly contagious and threatens poultry. The agency says mild strains affect domestic poultry and pigeons and more severe strains can kill chickens. It says Newcastle disease can decrease egg production in domestic birds and cause high numbers of sudden deaths in a flock, while wild birds can develop wing paralysis and be left unable to fly. It says the risk to humans is low if gloves are worn while handling infected birds, and that the disease was rarely found to kill wild birds before 1990. This report by The Canadian Press was first published June 18, 2025.
Globe and Mail
4 hours ago
- Globe and Mail
Biochips Market Projected to Reach USD 37.73 Bn by 2032, Growing at 16.0% CAGR
Biochips Market, By Product Type (DNA Chips, Protein Chips, Lab-on-chip Tissue Arrays, Cell Arrays), By End User (Biotechnology and Pharmaceutical Companies, Academic & Research Institutes, Hospitals and Diagnostic Centers, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) According to a recent report by Coherent Market Insights, Global Biochips market is estimated to be valued at USD 13.34 Bn in 2025 and is expected to reach USD 37.73 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 16.0% from 2025 to 2032. Increasing application of biochips in the field of proteomics, genomics and drug discovery can drive the market growth. Extensive R&D activities in the field of healthcare and growing demand for point-of-care testing and diagnostics can also boost demand for biochips during the forecast period. Global Biochips Market Key Takeaways According to Coherent Market Insights (CMI), the global biochips market size is projected to grow at a robust CAGR of 16%, from USD 13.34 Bn in 2025 to USD 37.73 Bn by 2032. Based on product type, DNA chips segment is expected to account for over two-fifths of the global biochips market in 2025. By end user, biotechnology and pharmaceuticals segment will likely hold a market share of 35.1% by 2025. North America is anticipated to retain its dominance, holding a market share of nearly 2/5 in 2025. As per CMIs' new biochips market analysis, Asia Pacific is expected to experience fastest growth during the forecast period. Growing Demand for Personalized Medicine Boosting Market Growth Coherent Market Insights' latest biochips market research report highlights major factors driving industry growth. One such prominent growth factor is the increasing demand for personalized medicine. Biochips are a key enabling technology in personalized medicine. They enable rapid and accurate analysis of an individual's genetic and proteomic profiles. This supports pharmacogenomics, helps in creating tailored treatment plans, and facilitates targeted therapies. These capabilities are especially valuable in managing complex diseases such as cancer. Thus, growing interest in personalized medicine will continue to provide a strong impetus for the growth of biochips market in the coming years. High Cost of Biochips and Adoption of Alternative Technologies Limiting Market Growth The future biochips market outlook looks promising. However, high cost of bioships and associated equipment, along with growing usage of alternative technologies, remain a significant barrier to broader market growth. Biochips are quite expensive due to their complex manufacturing processes and the need for specialized instrumentation. This high cost limits their accessibility, particularly among small and mid-sized laboratories, thereby reducing overall biochips market demand. Many end users are turning to alternative technologies like immunoassays, qPCR, and next-generation sequencing (NGS) due to their accuracy and cost-efficiency. This trend may also negatively impact the biochips market growth in the coming years. Growing Adoption in Disease Diagnostics Creating Lucrative Growth Opportunities Biochips are being increasingly used in the diagnosis of cancer, genetic disorders, and infectious diseases due to their high accuracy and speed. Their rising adoption in disease diagnostics is expected to create lucrative growth opportunities for biochip manufacturers during the forecast period. Rising incidence of chronic and infectious diseases, such as COVID-19, is creating a strong need for rapid diagnostics. This is expected to drive demand for biochips, as they offer fast and multiplexed detection of pathogens, making them ideal for point-of-care testing. Get Up to 25% Discount on the US Tariff Impact Analysis Report: Impact of AI on the Biochips Market Artificial Intelligence (AI) is making a profound impact on the biochips market. It enhances data analysis, diagnostics, and personalized medicine. AI algorithms significantly improve the accuracy and speed of disease detection by rapidly interpreting complex biological data produced by biochips. This powerful combination accelerates drug discovery and enables real-time health monitoring. With ongoing advancements in AI, new applications and efficiencies are expected to emerge. This evolution is poised to propel the biochips market toward greater scalability and precision in delivering advanced healthcare solutions. Emerging Biochips Market Trends Growing trend of miniaturization is significantly impacting the biochips market value. Key manufacturers are focusing on developing compact biochips (e.g. lab-on-a-chip systems) with improved features for use in diagnostics, drug discovery, and personalized medicine. Expanding applications of biochips in drug discovery is expected to foster sales growth. Biochips are increasingly used in drug discovery processes, particularly for gene expression analysis, toxicity profiling, and target identification. These applications are crucial for accelerating pharmaceutical R&D, thereby driving market growth. There is a growing emphasis on studying genes and proteins to better understand disease mechanisms, identify potential therapeutic targets, and develop personalized medicine approaches. This will likely create a strong demand for biochips in high-throughput research. Shift toward point-of-care testing (POCT) is expected to create lucrative growth avenues for biochip companies. Portable biochips are being widely used in POCT devices for faster diagnostics at the patient's location. Ongoing advancements in biochip manufacturing will also support market expansion. Improvements in microfluidics, microarray technology, and semiconductor biochip development are significantly enhancing capabilities of biochips. Analyst's View ' The global biochips market is expected to record robust growth, owing to increasing incidence of chronic and infectious diseases, rising demand for personalized medicines, and advancements in biochip manufacturing,' said senior analyst Abhijeet Kale. Current Events and Their Impact on the Biochips Market Competitor Insights Key companies listed in biochips market report: - LinguaFlex - Inspire Medical Systems, Inc. - Medtronic - LivaNova PLC - SomnoMed - Nihon Kohden Corporation - Siesta Medical Inc. - ResMed - Koninklijke Philips N.V. - Somnowell - Nyxoah SA - Fisher & Paykel Healthcare Limited - VYAIRE - Natus Medical Incorporated - Nox Medical - Drive DeVilbiss International - CLEVELAND MEDICAL DEVICES INC. - Advanced Brain Monitoring, Inc. - CONTEC MEDICAL SYSTEMS CO., LTD Key Developments In January 2025, Coherent Corp launched its new pinhole array biochips. These biochips are specifically designed for medical diagnostics, with a strong focus on gene sequencing applications. In May 2025, Archer Materials Limited partnered with Paragraf Limited for Biochip development. This partnership is intended to help Archer advance its Biochip for at-home testing of chronic kidney disease. Market Segmentation By Product Type DNA Chips Cancer Diagnosis and Treatment Gene Expression SNP Genotyping Genomics Drug Discovery Agricultural Biotechnology Others Protein Chips Proteomics Expression Profiling Diagnostics HTS Others Lab-on-chip IVD & POC Others Tissue Arrays Cell Arrays By End User Biotechnology and Pharmaceutical Companies Academic & Research Institutes Hospitals and Diagnostic Centers Others About Us:Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries. Media Contact Company Name: Coherent Market Insights Contact Person: Mr. Shah Email: Send Email Phone: + 12524771362 Address: 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States Burlingame City: Burlingame State: California Country: United States Website:
